Company Profile
Migco Pharmaceuticals was founded in 2004 to develop and bring to market new therapeutic products that will significantly improve the lives of those suffering from migraine. In the United States alone more than 28 million people suffer severe migraine with lives seriously disrupted during painful and prolonged attacks.
- Migco's promising lead compound, MGX-008, is based on a novel class of therapeutic compunds, and represents a new approach to migraine prevention.
- The compound is being rapidly progressed through the regulatory process, and its ability to reduce the incidence and severity of migraine headaches in long term refractory patients has been demostrated.
- A wholly owned subsidiary, MigcoBio, is integrating innovative research on the genetic gactors involved in migraine with the development of therapeutic treatments.
